Skip to main navigation
  • About
    • Leadership
    • Board of Directors
    • Pharmaceutical Partnerships
    • Meet F-Star Team Members
  • Technology
    • Our Platform
    • Publications
    • Intellectual Property
  • Pipeline
    • FS118
    • FS120
    • FS222
    • SB 11285
    • Partnerships
  • Investors
  • Careers
  • News
  • Contact Us
F-star Therapeutics
  • Careers
  • Investors
  • About
    • Leadership
    • Board of Directors
    • Pharmaceutical Partnerships
    • Meet F-Star Team Members
  • Technology
    • Our Platform
    • Publications
    • Intellectual Property
  • Pipeline
    • FS118
    • FS120
    • FS222
    • SB 11285
  • Contact

Press Releases

  • Overview
  • Press Releases
  • Events & Presentations
  • Stock Information
  • SEC Filings
  • Analyst Coverage
  • Annual Shareholder Meeting
  • Governance
  • IR Resources
  • Navigate
      • Overview
      • Press Releases
      • Events & Presentations
      • Stock Information
      • SEC Filings
      • Analyst Coverage
      • Annual Shareholder Meeting
      • Governance
      • IR Resources
  • Mar 08, 2023

    invoX Pharma Completes Acquisition of F-star Therapeutics, Inc.
  • Mar 07, 2023

    F-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX Pharma
  • Jan 26, 2023

    invoX Pharma and F-star Therapeutics issue Joint Statement
  • Dec 06, 2022

    F-star Therapeutics Presents Clinical Data on FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, at ESMO-IO 2022 Congress
  • Nov 07, 2022

    F-star Therapeutics Announces Publication of Phase 1 Dose-Escalation Trial of FS118 in Patients with Advanced Cancer and PD-L1 Resistance in Clinical Cancer Research
  • Aug 11, 2022

    F-star Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
  • Aug 04, 2022

    invoX Pharma Extends Tender Offer to Acquire F-star Therapeutics, Inc.
  • Jul 20, 2022

    F-star Therapeutics Announces a License Agreement with Takeda for a Novel Next-Generation Immuno-oncology Bispecific Antibody
  • Jun 23, 2022

    invoX Pharma to Acquire F-star Therapeutics, Inc. a Pioneering Next Generation Bispecific Discovery Platform and Clinical Programs
  • May 10, 2022

    F-star Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Next page Next >
  • Investor Contact
  • RSS
  • Print Page

About

  • Overview
  • Leadership
  • Board of Directors
  • Pharmaceutical Partnerships

Technology

  • Overview
  • Our Platform
  • Publications
  • Intellectual Property

Pipeline

  • Program Overview
  • FS118
  • FS120
  • FS222
  • SB 11285

 

  • Investors
  • Careers
  • News
  • Contact Us
  • About
    • Leadership
    • Board of Directors
    • Pharmaceutical Partnerships
    • Meet F-Star Team Members
  • Technology
    • Our Platform
    • Publications
    • Intellectual Property
  • Pipeline
    • FS118
    • FS120
    • FS222
    • SB 11285
    • Partnerships
  • Investors
  • Careers
  • News
  • Contact Us
  • LinkedIn
  • Twitter

Eddeva B920
Babraham Research
CampusCambridge, CB22 3AT, UK

245 First Street
Riverview II, Floor 18
Cambridge, MA 02142, USA

  • Disclaimer
  • Privacy Policy
  • Cookie Policy
  • Careers
  • Sitemap

© 2023 F-star Therapeutics, Inc.